NKGen Biotech Korea Co., Ltd. (KOSDAQ: A182400)
Health Care · Biotechnology · KR
₩—
— today · — 1Y
NKGen Biotech Korea Co., Ltd. (KOSDAQ: A182400) operates in the Biotechnology industry within the Health Care sector. The company is valued at $128.86M.
trading between 7.36K and 38.97K.
Tweenvest scores NKGen Biotech Korea Co., Ltd. across four factors: quality 34/100. Its strongest factor is quality.
A182400 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $128.86M
- Revenue (TTM)
- $5.25M
- P/E
- —
- EPS
- -18.01
- Dividend yield
- —
- Beta (5Y)
- 0.60
- 52-week high
- ₩38,973.75
- 52-week low
- ₩7,362.50
- Avg volume (3M)
- —
- Shares outstanding
- 18.00M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.13 | +0.61% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.85 | +0.00% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.79 | +0.72% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.94 | +1.16% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.55 | +0.73% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.42 | +13.34% |
Figures last refreshed Aug 18, 2026.